Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Leon-Nanodrugs GmbH manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 3 pending office actions currently active. These actions represent the company's current efforts to secure patent protection for its nanodrug technologies. The focus on biotechnology and pharmaceuticals indicates a specialized technical field with rigorous examination standards.
The 3 pending office actions are distributed across 3 distinct examiners and 3 distinct art units. This distribution between actions, examiners, and art units shows that each pending matter is being reviewed independently by a different official in a different technical division. There is no overlap in the personnel or the specific art units handling the company's current workload. For the practitioner, this means that the strategy for each of the 3 pending office actions must be tailored to the specific examiner and art unit involved.
SORKIN, DAVID L is the busiest examiner for the portfolio, currently handling 1 pending office action. Given that there are 3 pending office actions and 3 distinct examiners, the workload is split, with each examiner responsible for 1 action. This distribution ensures that no 1 examiner has a dominant influence over the company's current prosecution. The spread across 3 distinct art units further highlights the technical diversity of the pending applications within the pharmaceutical sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SORKIN, DAVID L | 1 | 67.5% | +13.0% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 51.8% | +27.5% |
| HOLT, ANDRIAE M | 1 | 49.5% | +23.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17595393 | METHOD FOR PRODUCING NANOPARTICLES | HOLT, ANDRIAE M | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17595393 | METHOD FOR PRODUCING NANOPARTICLES | HOLT, ANDRIAE M | 5d |
| 17999851 | METHOD FOR PRODUCING A LIPOSOME DISPERSION | ATKINSON, JOSHUA ALEXANDER | 28d |
| 18042460 | JET IMPINGEMENT REACTOR | SORKIN, DAVID L | — |
| Art Unit | Apps |
|---|---|
| 1774 | 1 |
| 1612 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18042460 | JET IMPINGEMENT REACTOR | SORKIN, DAVID L | 1774 | §103 | Non-Final OA | — | Pending | Feb 22, 2023 |
| 17999851 | METHOD FOR PRODUCING A LIPOSOME DISPERSION | ATKINSON, JOSHUA ALEXANDER | 1612 | §103DP | Final Rejection | 28d | Pending | Nov 24, 2022 |
| 17595393 | METHOD FOR PRODUCING NANOPARTICLES | HOLT, ANDRIAE M | 1614 | §103§112 | Final Rejection | 5d | Pending | Nov 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLeon-Nanodrugs GmbH has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
David L Sorkin has the most, with 1 of Leon-Nanodrugs GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
